Introduction
This review is in two parts. The first part deals with the natural history and pathophysiology of pulmonary embolism, and the second with diagnostic methods and approaches. Since pulmonary embolism is not a disease in its own right, but rather a complication of venous thromboembolism, the relevant aspects of that condition will also be included. The articles present the view that the two conditions are common, dangerous and difficult to diagnose, as well as being amenable to treatment: as much as possible of the evidence relevant to these conclusions is included. There is little convincing evidence that the incidence and mortality of the two conditions are decreasing, and as clinical practice becomes increasingly concerned with older and iller patients, they are likely to become more common and more difficult to diagnose. Natural history of venous thrombosis and pulmonary embolism Incidence The evidence that pulmonary embolism is predominantly a complication of venous thrombosis, which in the vast majority of cases has occurred in the deep veins of the legs, is compelling.1-4 Of course, in a small minority of cases, the thrombus may originate from other sitesmore proximal veins, indwelling venous cannulae, or the wall of the right ventricle -and even more rarely the embolus is not made of thrombus but of tumour, fat, or amniotic fluid. However, the main clinical problem is clearly pulmonary embolism secondary to thrombosis in the deep veins of the legs.
The natural history of both conditions is almost exclusively drawn from studies of hospital patients; we know little of the prevalence of either condition in the community, though they certainly occur and, by extrapolation from hospital experience, may be widely underdiagnosed. In hospital patients, deep venous thrombosis in the veins of the legs is a common event. This first became clear when radiolabelled fibrinogen techniques were employed. They showed that a quarter to a third of patients developed calf vein thrombosis following major surgery. 1,6 A later study by venography, which detects venous thrombosis above as well as below the knee, put the postoperative incidence at 40% .' Postmortem studies have suggested similar or higher figures in patients dying from medical, as well as surgical and traumatic conditions 1-3 and have also shown that thrombus may arise in proximal leg veins independently of below-knee thrombosis.
Generally speaking, below-knee venous thrombosis is harmless; it does not cause clinically important pulmonary emboli or long-term local morbidity .7-9 This is not, however, to say that it is safe and needs no treatment. Although it may resolve spontaneously, it can recur and may propagate to involve the proximal veins of the thigh in up to a third of patients, particularly those who are symptomatic .8, 10 Then it becomes a menace.
Untreated, proximal leg vein thrombosis poses a risk of pulmonary embolism in the region of 50%. 7, 8, 11 Taken at face value, these figures suggest that we should expect a very significant proportion of high risk patients to have pulmonary emboli, which experience suggests is implausible.
However, it may not be; postmortem studies of consecutive or unselected series of patients dying in hospital have consistently shown a prevalence of pulmonary embolism of 12-26% . [12] [13] [14] [15] [16] Even this range may be an underestimate: Morrell and Dunnill 17 and Freiman et al. 18 showed that the observed prevalence depends on the care with which emboli are sought. When they were very careful, they found evidence of pulmonary embolism in 52% and 64% of their series respectively, when routine methods had shown only 12% and 33%. Of course such series are not of consecutive patients; they study only those who were most sick. However, an investigation which did study consecutive patients undergoing major lower-limb surgery showed a not dissimilar picture; there was convincing evidence of postoperative pulmonary embolism in 23%. '9 Most of the studies quoted here have focused on surgical patients, but the risk from proximal leg vein thrombosis, and the occult nature of many pulmonary emboli, is general. Dorfman et al. ,&dquo; studying an ambulatory group of patients with proximal leg vein thrombosis, none of whom had had recent pelvic or orthopaedic surgery, found evidence strongly suggestive of pulmonary embolism in 35%. Moser and LeMoine7 reported an even higher figure of 53% in a mixed group of medical, surgical and trauma patients.
The reason why these statistics may appear to conflict with clinical experience seems to be that many emboli go undetected. First, in the three studies mentioned above, emboli were diagnosed in a total of 73 patients, but only 5 (7%) were symptomatic. Secondly, many of the cases in postmortem series showed only small emboli, unlikely to have significant haemodynamic effects, and often unaccompanied by pulmonary infarction. Thus, they lacked the features likely to provoke symptoms and signs, and the comment was frequently made that only a small proportion of embolic episodes had been diagnosed before death; typically less than a third. This tendency was particularly noticeable in the elderly and in patients with cardiac failure where only one in ten episodes were diagnosed clinically.
Outcome in untreated pulmonary embolism
It follows from the facts reported above that as well as being asymptomatic, many pulmonary emboli are harmless. However, there is good evidence that pulmonary embolism tends to recur if left untreated. First, residual thrombus can be detected in the leg veins of a majority of patients with pulmonary embolism,2&copy;22 and in half or more it involves the proximal veins23: and secondly, patients with major pulmonary embolism frequently exhibit evidence of prior minor embolism This tendency of emboli to be recurrent, and in some cases very large, means that the clinical outcome in untreated pulmonary embolism is poor, with death rates of diagnosed cases in the region of 30%. 27,28 Many of these deaths occur in patients with other serious disease, when pulmonary embolism may only be contributory, but it is causative in about a third, including some with an otherwise excellent prognosis, for example those undergoing elective surgery or with benign medical conditions. Bell underlying disease such as occult malignancy. The advantage that might be gained for this small group of patients by a longer period of treatment has to be balanced against the risks, which accumulate with time (see below). It has also been suggested on the basis of a retrospective survey that the period of treatment may be safely reduced to six weeks in patients with a first episode and no predisposing condition,38 but this has not been established by prospective trial, unlike the other conclusions.
In patients being treated for recurrent thromboembolism, stopping anticoagulants after three months carries a 20% risk of recurrence during the ensuing 12 months39; therapy should probably be continued for at least this length of time.
Thrombolytics
With all anticoagulant regimes there will be an incidence of late lower-limb venous insufficiency and there may be deaths in the very early stages of treatment of massive embolism. For these reasons, thrombolytic agents have been studied as an alternative to heparin in the initial stages of treatment. Goldhaber et al.4° have summarized the results of a number of trials which show that they are effective in deep venous thrombosis; they lead to more rapid resolution of thrombi than heparin and in up to 30% of cases may restore normal anatomy. There is also some evidence that they improve the long-term prognosis.41 Their overall role is not yet clearcut because cost, higher risks of haemorrhage and a wider range of contraindications all bear on their clinical usefulness, but at present there are good grounds for recommending their use in acute, major iliofemoral thrombosis, if only because of its appalling long-term prognosis when treated in other ways.42
In pulmonary embolism the role of thrombolytic therapy is also debated. Clot lysis is faster in the early stages with streptokinase 43-46 and urokinase 47 than with heparin, and a similar advantage has more recently been shown for tissue plasminogen activator (r-TPA) compared to heparin .48 Direct comparison of r-TPA with urokinase 49 suggested that r-TPA may achieve early lysis in a higher proportion of patients, but the advantage lasts less than 24 hours. Thus, thrombolytic therapy would appear appropriate in the management of massive acute embolism; but none of the trials to date has shown an actual reduction of mortality for thrombolysis compared to heparin and its advantages at present remain theoretical.
The role of surgical intervention to prevent further emboli reaching the lung50,5 I and to remove fresh 52 or organized 53 thrombus from the pulmonary vascular bed, are beyond the scope of this article but the cited references deal with the current position.
The risks of treatment
A wealth of studies demonstrate that there is a risk of haemorrhage with anticoagulants, both oral and systemic. However, many of these studies have been retrospective, have not specified criteria for inclusion (or more importantly exclusion) and have used different tests and criteria for anticoagulation control. In addition, they have predominantly examined patients with indications for anticoagulation other than thromboembolism. Patients with thromboembolic disease tend to be at higher risk from anticoagulants than many others because they are usually already ill from another condition or recovering from surgery or trauma. In addition, relative contraindications to anticoagulants, which in less threatening clinical situations might be respected, may have to be ignored. We should, therefore, confine attention to anticoagulant risk in venous thrombosis and pulmonary embolism.
Heparin Table 1 summarizes the reported incidence of severe or fatal haemorrhage in patients given heparin as initial treatment for venous thromboembolic disease. The data includes much of the original evidence on the dangers of using heparin by intermittent injection but in addition, illustrates that even when heparin is given by continuous infusion for a limited period there is a 5% risk of major haemorrhage. Major haemorrhage is here defined as either fatal or severe enough to prompt transfusion or cessation of treatment. In the majority of these studies, over-anticoagulation was not a good predictor of risk; rather, careful control of dosage was important to prevent extension of the original disease due to undertreatment. Some other conditions, including chronic cardiopulmonary disease as well as anatomical lesions like peptic ulcers or malignancy, do however predispose to bleeding, and in some studies, the elderly appeared to be particularly at risk. However, this may be because they have a higher prevalence of such risk factors.
Thrombolytics
With thrombolytic agents, allergic reactions are a problem since prior exposure to streptococci is universal and streptokinase is antigenic. Febrile reactions are common and anaphylaxis may rarely occur, but in general haemorrhage is still the most dangerous adverse reaction. Several of the studies in Table 1 were comparative trials of streptokinase and heparin,46,s9,61 and the National Co-operative Stud y47 provides information on urokinase. In addition, Goldhaber et al. 40 summarized the results of other comparative trials. These sources uniformly demonstrate that thrombolytic agents carry a risk of major haemorrhage two to three times higher than that shown for heparin in Table 1 (part a). 
Warfarin
A risk of haemorrhage also exists with warfarin. Table 2 gives data for patients treated with oral warfarin as follow-up therapy after heparin. The numbers are small and in comparison with much larger series which have examined warfarin risk in conditions such as atrial fibrillation or heart valve prosthesis, the incidence of major bleeding in Table 2 seems very high. However, there are good reasons for accepting the results. All the studies quoted are prospective trials in which warfarin dosage was well controlled; and one other large retrospective survey in which the incidence of major bleeding was given for the first three months of treatment, 38 yielded a comparable figure (10%). The apparent safety of other studies probably reflects their relative sparsity of risk factors for haemorrhage and the fact that haemorrhage rates' for warfarin are usually reported 'per patient year', which dilutes the early risk in patients treated for long periods.
The figures in Tables 1 and 2 imply that there are very real risks from anticoagulants and thrombolytics in the treatment of venous thrombosis or pulmonary embolism: probably something in excess of one in eight for major haemorrhage and one in two hundred for mortality. It follows that a strong case can made for exhaustive investigation of all suspected cases. Except in desperately ill patients, the mortality and morbidity of even the most invasive investigation, pulmonary angiography, is well below these figures.
The pathophysiology of pulmonary embolism Vascular pathophysiology
The behaviour of thrombus once it has arrived in a pulmonary artery has been reasonably well defined by a combination of studies of experimental thromboembolism in animals and serial pulmonary angiography in man. Following embolism, there is an initial degree of obstruction which may decrease very rapidly -within hours as judged by serial angiography in dogs. Since this occurs without any change in the appearance of the thrombi apart from slight movement, 66 the first step in resolution may be the mechanical movement of the thrombi which reduces the degree of obstruction. An alternative suggestion is that the initial degree of obstruction is amplified by humoral or reflex effects. In animal experiments, there is evidence that vasoactive amines released from platelets in the thrombi may cause local vasoconstriction, and this effect can be blocked by appropriate antagonists.67.68
Whatever the mechanism, rapid resolution of shock often occurs clinically (see below), and this is followed by dissolution of the thrombus. In dogs, which have a very potent thrombolytic mechanism, this may be very rapid as the thrombus size is considerably reduced within three hours and accelerated by heparin, perhaps by preventing further accretion of platelets. 69 Complete resolution then follows over a time scale of one to seven days.7°I n man, the process of dissolution appears to be slower, though information is incomplete. Serial angiographic studies have shown that complete resolution may occur as early as nine days,7' but usually takes longer and may be incomplete after many weeks. 43,72 Studies with Table 2 Major haemorrhage dunng oral anticoagulant therapy serial scanning73-76 can be repeated more freely than angiography and have fleshed out this picture. The rate of scan recovery was found to depend on the severity of the embolism, the presence of pre-existing cardiovascular disease and the patient's age. Mild cases could show complete recovery within a few days and 60% or more were normal by 20 weeks. In severe cases, the earliest complete recovery was seen very much later, and even after many weeks severe vascular obstruction was still present in some patients and only a minority were completely normal. One-third of this group still had perfusion defects after a year, consistent with the observation that previous pulmonary embolism can be a cause of 'false positive' scans.
The haemodynamic consequences of acute pulmonary embolism (which is unheralded in more than 50% of cases) depend on its scale. Massive embolism, implying presentation with shock, and obstruction of more than half the major pulmonary arteries in patients without preexisting cardiopulmonary disease, 26 may be rapidly fatal: less than half the patients in two surveys of massive fatal embolism survived the first hour. 24,77 In those who do survive, the main physiological consequence is an increase in pulmonary vascular resistance, which rises steeply if more than 50% of the pulmonary vascular bed is obstructed.78 It follows that the haemodynamic consequences depend on the prior state of the pulmonary vascular bed as well as the scale of the embolism; thus, relatively minor emboli can be very serious in patients with pre-existing pulmonary hypertension. 79
The consequences of massive embolism in previously normal individuals who survive is a low cardiac output accompanied by right ventricular failure. 26 However, the pulmonary artery pressure is only modestly raised (typically to a mean pressure of below 40mmHg.26,43,79,8°T his is often attributed to an inability of the thin-walled right ventricle to generate high pressures. Animal studies, however, suggest that ischaemia of the right ventricular wall, provoked by a combination of reduced aortic pressure and increased right ventricular end-diastolic pressure, may be involved.81 In contrast, patients with preexisting pulmonary vascular disease may have right ventricular hypertrophy and generate very high pressures acutely. Although this may have acute survival value, it carries an adverse prognosis in the long-term. 112 A minority of early survivors remain in shock despite treatment, and may die, their cardiac status possibly compromized further by myocardial ischaemia secondary to tachycardia and hypotension.
However, Miller and Sutton26 found evidence that haemodynamic function began to improve very early in survivors, as did Dalen et al. 43 and a majority of the milder cases in the latter study had normal pulmonary artery pressures within 10-21 days.
In keeping with this early improvement, the long-term prognosis in pulmonary embolism survivors is good. In a follow-up to The effect was by no means always seen in subsequent studies; Severinghaus et al. 91 suggested that its extent might depend upon the anaesthetic used among other things. They used a tracheal divider to study the function of each lung separately whilst one pulmonary artery was occluded with a balloon catheter. They found that there was a shift of ventilation away from the occluded lung in most animals which could be prevented by the inhalation of 6% CO, into the occluded lung. They suggested that the effect was due to bronchoconstriction of the very small airways, since low pCO, had been previously shown to do this and they speculated that the pCO, of the smooth muscle of the large airways would be normal as they were perfused with blood from the bronchial arteries. This has still not been settled; a later study in dogs92 showed that there were two events. First, there was a very rapid decrease in dynamic compliance of the lung, suggesting patchy peripheral airway obstruction; later, there was an increase in airways resistance. They suggested the initial effect was due to serotonin released from the clot they injected, and washed downstream to affect the airways perfused by the local pulmonary circulation. The second effect, which was blocked by cutting the vagus, was preceded by a fall in lung volumes, and they thought this was a reflex triggered by deflation. Both effects were very short-lived (one to three minutes), and may be different from the effect described by Severinghaus et al. (who saw the effect last as long as the occlusionup to an hour -in some animals and who, of course, were not using platelet-containing thrombi to obstruct the pulmonary arteries).
The fact that the reduction of ventilation is due to bronchoconstriction has been confirmed by several studies which_ employed direct visualization of the small airways. Tantalum bronchography in dogs and cats showed bronchoconstriction of small airways (from 3mm downwards) which persisted for at least 40 minutes and was reversed by bronchodilator.93
Similar results were obtained in two other animal studies which examined airway calibre directly. 94,95 Evidence for involvement of serotonin is that both serotonin antagonists and heparin (which blocks the thrombin-induced release of serotonin from platelets) prevent bronchoconstriction caused by the release into the pulmonary circulation of autologous venous
ClotS.96
Animal studies using isotopes to study ventilation and perfusion have also demonstrated transient reduction of ventilation following embolic or balloon obstruction of the pulmonary vasculature. Wolfe and Sabiston 97 demonstrated mild impairment of ventilation, which cleared within 48 hours, in lungs subjected to massive (main or lobar artery) occlusion. Isawa et al. 98 confirmed the effect and showed that the impairment of ventilation occurred almost immediately. In their experiments, it lasted less than four hours, though it recurred later in those animals with pulmonary complications such as infarction or collapse of the embolized lung.
Alderson et a1.99 confirmed that ventilation was only impaired after emboli had obstructed a large pulmonary artery.
Human studies
Acute reduction in ventilation of lung areas involved in pulmonary vascular occlusion has also been well-documented in man. Swenson et al.1°O occluded the pulmonary artery unilaterally with balloon catheters whilst measuring various ventilatory parameters with a Carlens tube. They found a fall in ventilation on the occluded side, which could be reversed by adding 6% CO, to the air breathed on that side. Over periods of occlusion lasting up to 90 minutes they found no change in overall ventilation or blood gases.
Evidence also exists in clinical pulmonary embolism. Wheezing or impaired airways function has been reported a number of times in acute pulmonary embolism, lasting for hours or days and sometimes severe enough to lead to an initial diagnosis of asthma. [101] [102] [103] [104] [105] [106] Possible mechanisms do not appear to have been explored in man, but the frequency with which eosinophilia, atopy, or other indications of allergy have been noted, suggests that the reaction may occur particularly in subjects with very reactive airways. Local hypocapnoea seems unlikely to be the cause; alveolar pCO, has to fall to 25mmHg before the effect is seen,'°7 and calculations based on ventilation-perfusion ratios suggest this is unlikely 1118 ; however, the effects of C02 breathing or serotonin antagonists do not appear to have been examined. This is not surprising; it should be emphasized that bronchoconstriction is a rare and transient clinical observation in pulmonary embolism.
Parenchymal pathophysiology
The pathological processes which may take place in the lung parenchyma supplied by an embolised artery are poorly understood.
Infarction, which would be the outcome in many vascular beds following obstruction of the supplying artery, is by no means predictable.
With massive central embolism it is rare. The favoured explanation is that of Virchow,109 who found no infarction in the lung of the dog if one pulmonary artery was tied and postulated that there is collateral flow from the bronchial arteries into the pulmonary artery distal to the ligature. There is a good deal of evidence to support this view. If a pulmonary artery is ligated, the bronchial arteries supplying the lung distal to it hypertrophy&dquo;o and carry a considerable blood flow to the pulmonary capillary bed&dquo;' : if contrast material is injected into the aorta of a dog which has had a major branch of the pulmonary artery tied, it appears in the pulmonary arterial tree distal to the site of occlusion. 112 It should also be remembered that the lung has a third potential source of oxygen, via the airway.
With less severe degrees of embolism affecting peripheral vessels, the clinical presentation in very many cases suggests that infarction has occurred. The patient presents with pleuritic pain and perhaps an effusion and there is haemoptysis and an infiltrate on the chest X-ray. However, experimental&dquo;3 and postmortem 16,25,114 studies provide compelling evidence that only a minority of emboli lead to infarction, and that these are largely confined to patients with pre-existing lung disease or heart failure. Dalen et al. 115 examined this paradox in a retrospective series of welldocumented pulmonary embolism cases. They confirmed that the 'infarct' features were seen in a very high proportion of patients with submassive emboli, regardless of whether they had pre-existing heart disease; but when they examined the resolution of these features, there was a clear correlation between pre-existing heart disease and slow resolution of the X-ray infiltrate. They postulated that the clinical presentation of infarction is actually the presentation of pulmonary haemorrhage, which may or may not, depending on the haemodynamic status of the patient, progress to lung necrosis and true infarction. In patients with a high pulmonary venous pressure, haemorrhage would be less well resorbed and true infarction much more likely.
Consistent with this, it has been shown in dogs that infarction did not follow lobar pulmonary artery occlusion unless the pulmonary veins were also obstructed. &dquo;6 Furthermore, the classic description of infarction'1' was actually of haemorrhage followed after about 48 hours by necrosis of lung parenchyma. The acute stage corresponded with the appearance of an infiltrate on the chest X-ray and the later stage by the appearance of a fibrotic scar, with a linear streak and/or pleural reaction on the chest X-ray.lI8 At present, this sequence of events seems to be the most plausible hypothesis to explain the behaviour of submassive embolism.
Other processes may affect the pulmonary parenchyma. In experimental pulmonary artery occlusion, atelectasis (commonly seen in patients) occurs after 24-72 hours as well as alveolar haemorrhage. &dquo;y In fact, atelectasis occurs at an early stage after experimental pulmonary artery occlusion, with slow resolution (15 days plus) and preservation of normal alveolar structure. This is discussed by Finley et al.'2° who showed that the surface tension of alveolar extracts from lung distal to the occlusion rises initially and then falls slowly. They concluded that the production of surfactant was initially defective and later recovered, and that this was the cause of the loss of volume. Pulmonary oedema may also occur in experimental pulmonary embolism.,121 and has been described as a rare accompaniment of pulmonary embolism in main. 122-124 The suggested mechanism is an increase in endothelial permeability caused by the release of humoral agents from local thrombus, but this remains speculative.
Hypoxaemia
Arterial hypoxaemia is extremely frequent in acute pulmonary embolism. Occasionally it has been claimed to be constant, 125 and thus to be a prerequisite to the diagnosis, but several series have documented a few cases (10-15%) with normal arterial p02.~~~ Some of these were probably, or definitely, raised into the normal range by the hyperventilation which is so common in acute embolism, (i.e. there is an abnormally widened alveolar-arterial oxygen gradient) but in those reports which permit calculation of this gradient, a small minority remain in whom gas exchange was unequivocally normal. 127, 129 On the other hand, hypoxaemia, with or without hypocapnoea, is so common in acute lung disease generally that its presence is unhelpful in the diagnosis of pulmonary embolism, though it is important to the management.
Several mechanisms may contribute to hypoxaemia and there is still some uncertainty about their relative roles. Ventilation-perfusion mismatching is such a common cause in other lung diseases that it is an obvious candidate until one reflects that underventilation, rather than underperfusion, is the form of mismatching that causes hypoxaemia; local reduction of perfusion simply causes wasted ventilation with a raised alveolar dead space.'3o However, this is to ignore those areas to which the blood flow is diverted, where relative underventilation may occur, and has been calculated to account for the hypoxaemia in mild pulmonary embolism. 127 In severe embolism this appears to be less important because pulmonary blood flow is reduced overall. Instead, another mechanism appears important, namely a widening of the arteriovenous oxygen difference due to the low cardiac output which delivers very desaturated blood to the lung capillaries. 13 Areas with relatively low ventilationperfusion ratios cannot correct this desaturation completely and arterial hypoxaemia follows. Paradoxically, if embolism is very severe, ventilation may be stimulated to extremely high levels by the metabolic acidosis which accompanies the low cardiac output132 and may correct the hypoxaemia. 133
Other mechanisms may also contribute to hypoxaemia. One of these is 'shunting' of blood so that it bypasses aerated lung. This may occur within the lungs themselves; for example, in areas of atelectasis or pulmonary oedema, or rarely in the heart where blood may pass from the right to the left atrium across a patent foramen ovale in patients who develop a high systemic venous pressure following embolism. 134 Finally, there may be a minor contribution from diffusion limitation. '3' 
